Upharmacia September 2017
PHARMA MARKET NEWS
Biofarma ’ s Plant Caught on Fire
On Sep 25 , the Biofarma ' s facilities in Bila Tserkva had caught on fire . Luckily , no one was injured , and the fire was localized . The fire damaged warehouses only . The causes of the fire are still unknown .
The fire destroyed only packages and raw materials . The production on the plant was resumed on Sep 28 .
Biofarma had built the plant in Bila Tserkva in 2014 investing about US $ 42 mio . The company plans to complete the construction of the new workshop of the plant in 2Q 2018 through investing about US $ 40 mio .
Biofarma is the only producer of blood preparations in the CIS . It produces more than 20 immunobiological preparations from donor blood , preparations obtained in the technology of recombinant DNA and probiotics .
Takeda Ukraine
Obtained OTC
Drugs from Unipharm
Ukraine ’ s RO of Unipharm finished the deal with Takeda Ukraine , according to which the subsidiary of the Japanese company obtained the Unipharm ’ s line of OTC drugs and food supplements . Unipharm will continue managing its current portfolio in 2018 . During the period of integration of Unipharm ’ s products into Takeda ’ s portfolio , Unipharm will keep its operations and will begin active development in other pharmaceutical segments , the company ’ s officials said .
In 1HY 2017 , Takeda was 9 th company on the retail drug market of Ukraine by sales in values .
Farmak Abandons Plans to Start Production of Vaccines
Ukrainian pharmaceutical market leader Farmak would not open production of vaccines in the near future the CEO of the company Augustin Dubnicka stated . Thus , the company abandons the plans , which were announced earlier .
“ From our side , as a national producer , it would be more rational to create medicines in those areas where we are competent , for example , endocrinology ,” Mr Dubnicka said .
Farmak considers projects on contract production of APIs at its facilities in Shostka . The company plans to invest UAH 230 mio in the development of its projects in 2017 . At the end of the year , the company retained the 15th position on retail drug market by sales .
Arterium
Launched Three New Brands
In Aug , Arteruim Corporation launched onto Ukrainian market three new drugs . Hepametion ( ademetionine ) for the treatment of liver diseases ; it is used in the treatment of diseases accompanied by intrahepatic cholestasis .
Amodern Neo ( amorolfine ) a varnish for the treatment of fungal infection of the nails . Cholelesan ( comb drug ) is a vegetal choleretic drug , which is intended for the treatment of gallbladder diseases , as chronic cholecystitis and biliary dyskinesia .
Arterium has about 140 brands in its portfolio ; antibacterial products are its primary focus . It held the second position on the local retail pharmaceutical market in 1HY 2017 .
Sanofi Aventis Ukraine Seeks to File Claim to International Court to Protect Investment in Ukraine
" The new refusal of business courts to conduct an examination of original documents , using which fraudsters are trying to seize almost UAH 50 million belonged to Sanofi Aventis Ukraine , was the reason for filing the claim " the company said in a press release .
The case is heard in Ukrainian courts with numerous violations , disregarding for the arguments and evidence of Sanofi Aventis Ukraine , including examinations proving the forgery of documents .
" These fraudulent actions occur when the Ukrainian authorities are inactive along with the active assistance of representatives of the State Enforcement Service ," the press service said .
6 www . upharma-c . com